Literature DB >> 29541851

Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?

Emanuela Traini1, Rocco Bellantone1, Serena Elisa Tempera1, Salvatore Russo1, Carmela De Crea1, Celestino Pio Lombardi1, Marco Raffaelli2.   

Abstract

PURPOSE: Indications and advantages of parathyroidectomy in patients with normocalcemic primary hyperparathyroidism (NHPT) are still matter of debate. We aimed to compare clinical presentation and surgical outcome between normocalcemic and hypercalcemic forms in a consecutive series of patients who underwent parathyroidectomy for primary hyperparathyroidism.
METHODS: Data of 731 consecutive patients were reviewed and retrospectively compared according to normocalcemic (group A) and hypercalcemic (group B) phenotypes.
RESULTS: No significant differences were found between the two groups concerning demographics and symptomatic onset. Mean preoperative PTH levels were significantly higher in group B (252.0 ± 320.7 pg/ml vs 151.7 ± 112.0; p < 0.001). Mean PTH levels in first postoperative day were significantly lower in group B (30.9 ± 26.2 vs 22.7 ± 20.7; p < 0.001). No significant difference in overall accuracy of preoperative imaging studies was found. Significantly more patients in group A underwent bilateral explorations (83 vs 255; p < 0.05). The rate of multigland disease was significantly higher in group A (13.0 vs 6.8%; p < 0.05). At a mean follow-up period of 72.9 ± 46.8 months, all but three patients, among the 96 of group A who completed follow-up evaluation, were biochemically cured. The remaining patients had persistent high PTH values. Among NHPT patients who had target organ disease before parathyroidectomy, improvement in bone density and in kidney stones was observed in 41.7 and 40.0%, and stability in 50.0 and 60.0% respectively.
CONCLUSION: In normocalcemic patients, parathyroidectomy is as safe and effective as in hypercalcemic patients. In the presence of symptoms and/or target organ disease, parathyroidectomy may have a positive effect on the outcome of NHPT patients.

Entities:  

Keywords:  Hyperparathyroidism; Normocalcemic; Outcome; Parathyroidectomy

Mesh:

Substances:

Year:  2018        PMID: 29541851     DOI: 10.1007/s00423-018-1659-0

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  28 in total

1.  Is Normocalcemic Primary Hyperparathyroidism Harmful or Harmless?

Authors:  Gang Chen; Ying Xue; Qiongyao Zhang; Ting Xue; Jin Yao; Huibin Huang; Jixing Liang; Liantao Li; Wei Lin; Lixiang Lin; Lidan Shi; Liangchun Cai; Junping Wen
Journal:  J Clin Endocrinol Metab       Date:  2015-02-10       Impact factor: 5.958

2.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

Review 3.  Normocalcemic primary hyperparathyroidism.

Authors:  Natalie E Cusano; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

Review 4.  Nephrolithiasis and renal calcifications in primary hyperparathyroidism.

Authors:  Lars Rejnmark; Peter Vestergaard; Leif Mosekilde
Journal:  J Clin Endocrinol Metab       Date:  2011-06-06       Impact factor: 5.958

Review 5.  Normocalcemic hyperparathyroidism.

Authors:  J M Monchik
Journal:  Surgery       Date:  1995-12       Impact factor: 3.982

6.  The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.

Authors:  Scott M Wilhelm; Tracy S Wang; Daniel T Ruan; James A Lee; Sylvia L Asa; Quan-Yang Duh; Gerard M Doherty; Miguel F Herrera; Janice L Pasieka; Nancy D Perrier; Shonni J Silverberg; Carmen C Solórzano; Cord Sturgeon; Mitchell E Tublin; Robert Udelsman; Sally E Carty
Journal:  JAMA Surg       Date:  2016-10-01       Impact factor: 14.766

Review 7.  Video-assisted minimally invasive parathyroidectomy: benefits and long-term results.

Authors:  Celestino P Lombardi; Marco Raffaelli; Emanuela Traini; Carmela De Crea; Salvatore M Corsello; Rocco Bellantone
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

8.  Intraoperative PTH monitoring during parathyroidectomy: the need for stricter criteria to detect multiglandular disease.

Authors:  Celestino Pio Lombardi; Marco Raffaelli; Emanuela Traini; Enrico Di Stasio; Cinzia Carrozza; Carmela De Crea; Cecilia Zuppi; Rocco Bellantone
Journal:  Langenbecks Arch Surg       Date:  2008-07-24       Impact factor: 3.445

9.  Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: More Stone than Bone?

Authors:  L M Amaral; D C Queiroz; T F Marques; M Mendes; F Bandeira
Journal:  J Osteoporos       Date:  2012-03-25

10.  Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden.

Authors:  Georgios Kontogeorgos; Penelope Trimpou; Christine M Laine; Göran Oleröd; Anders Lindahl; Kerstin Landin-Wilhelmsen
Journal:  Clin Endocrinol (Oxf)       Date:  2015-06-15       Impact factor: 3.478

View more
  8 in total

Review 1.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

2.  Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia.

Authors:  Manabu Okada; Yoshihiro Tominaga; Tetsuhiko Sato; Toshihide Tomosugi; Kenta Futamura; Takahisa Hiramitsu; Toshihiro Ichimori; Norihiko Goto; Shunji Narumi; Takaaki Kobayashi; Kazuharu Uchida; Yoshihiko Watarai
Journal:  BMC Nephrol       Date:  2022-06-17       Impact factor: 2.585

3.  How should we define cure after parathyroidectomy for normocalcemic primary hyperparathyroidism? A retrospective cohort study.

Authors:  Oscar Cano-Valderrama; Santiago Ochagavía; Concepción Sanabria; Cristina Familiar; Jesús Díaz; Sara Picazo; Patricia Sáez-Carlin; Antonio J Torres
Journal:  Updates Surg       Date:  2021-06-07

4.  Surgical management of MILD hyperparathyroidism.

Authors:  Adèle Lecourt; Gwenaëlle Creff; Paul Coudert; Olivier De Crouy Chanel; Pascal Guggenbuhl; Franck Jegoux
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-30       Impact factor: 2.503

5.  Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History.

Authors:  Marian Schini; Richard M Jacques; Eleanor Oakes; Nicola F A Peel; Jennifer S Walsh; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

Review 6.  Normocalcaemic primary hyperparathyroidism: what is the role of parathyroid surgery?

Authors:  Nivaran Aojula; Shahab Khan; Neil Gittoes; Zaki Hassan-Smith
Journal:  Ther Adv Endocrinol Metab       Date:  2021-02-27       Impact factor: 3.565

Review 7.  Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach.

Authors:  Guido Zavatta; Bart L Clarke
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-01

8.  Normocalcaemic hyperparathyroidism and primary hyperparathyroidism: least significant change for adjusted serum calcium.

Authors:  Marian Schini; Richard Jacques; Eleanor Oakes; Nicola Peel; Jennifer S Walsh; Richard Eastell
Journal:  Eur J Endocrinol       Date:  2021-01       Impact factor: 6.664

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.